Acura’s Pain Drug Fails Test By: MarketMinute » Stock News August 27, 2013 at 09:42 AM EDT Acura Pharmaceuticals Inc. (Nasdaq: ACUR) reported that its abuse resistant pain medication failed a mid-stage clinical trial. The stock price fell 37 cents to close at $1.50.